Rationale for adjuvant idiotypic vaccination after high-dose therapy for multiple myeloma

Volker L. Reichardt; Craig Y. Okada; Keith E. Stockerl-Goldstein; Bjarne Bogen; Ronald Levy

Rationale for adjuvant idiotypic vaccination after high-dose therapy for multiple myeloma

Volker L. Reichardt, Craig Y. Okada, Keith E. Stockerl-Goldstein, Bjarne Bogen, Ronald Levy

Research output: Contribution to journal › Article › peer-review

Abstract

With conventional therapy, multiple myeloma (MM) has a poor prognosis. During the last few years, it has become clear that high-dose chemotherapy with autologous stem cell support can increase overall survival of MM patients, but further improvement in outcome is desperately needed. The monoclonal immunoglobulin (Ig) produced by the MM cells called idiotypes (Id) is a tumor-specific antigen due to unique antigenic determinants that are localized in the variable regions of the Ig molecule. Conceivably, Id immunization of MM patients in complete remission could further increase survival. Here we renew the scientific basis for such Id immunization.

Original language	English (US)
Pages (from-to)	157-163
Number of pages	7
Journal	Biology of Blood and Marrow Transplantation
Volume	3
Issue number	3
State	Published - Aug 1997
Externally published	Yes

Keywords

High-dose therapy
Idiotypic vaccination
Multiple myeloma

ASJC Scopus subject areas

Hematology
Transplantation

Cite this

@article{3b51d1806ebc4a849118138991629ac9,

title = "Rationale for adjuvant idiotypic vaccination after high-dose therapy for multiple myeloma",

abstract = "With conventional therapy, multiple myeloma (MM) has a poor prognosis. During the last few years, it has become clear that high-dose chemotherapy with autologous stem cell support can increase overall survival of MM patients, but further improvement in outcome is desperately needed. The monoclonal immunoglobulin (Ig) produced by the MM cells called idiotypes (Id) is a tumor-specific antigen due to unique antigenic determinants that are localized in the variable regions of the Ig molecule. Conceivably, Id immunization of MM patients in complete remission could further increase survival. Here we renew the scientific basis for such Id immunization.",

keywords = "High-dose therapy, Idiotypic vaccination, Multiple myeloma",

author = "Reichardt, {Volker L.} and Okada, {Craig Y.} and Stockerl-Goldstein, {Keith E.} and Bjarne Bogen and Ronald Levy",

year = "1997",

month = aug,

language = "English (US)",

volume = "3",

pages = "157--163",

journal = "Biology of Blood and Marrow Transplantation",

issn = "1083-8791",

publisher = "Elsevier Inc.",

number = "3",

}

TY - JOUR

T1 - Rationale for adjuvant idiotypic vaccination after high-dose therapy for multiple myeloma

AU - Reichardt, Volker L.

AU - Okada, Craig Y.

AU - Stockerl-Goldstein, Keith E.

AU - Bogen, Bjarne

AU - Levy, Ronald

PY - 1997/8

Y1 - 1997/8

N2 - With conventional therapy, multiple myeloma (MM) has a poor prognosis. During the last few years, it has become clear that high-dose chemotherapy with autologous stem cell support can increase overall survival of MM patients, but further improvement in outcome is desperately needed. The monoclonal immunoglobulin (Ig) produced by the MM cells called idiotypes (Id) is a tumor-specific antigen due to unique antigenic determinants that are localized in the variable regions of the Ig molecule. Conceivably, Id immunization of MM patients in complete remission could further increase survival. Here we renew the scientific basis for such Id immunization.

AB - With conventional therapy, multiple myeloma (MM) has a poor prognosis. During the last few years, it has become clear that high-dose chemotherapy with autologous stem cell support can increase overall survival of MM patients, but further improvement in outcome is desperately needed. The monoclonal immunoglobulin (Ig) produced by the MM cells called idiotypes (Id) is a tumor-specific antigen due to unique antigenic determinants that are localized in the variable regions of the Ig molecule. Conceivably, Id immunization of MM patients in complete remission could further increase survival. Here we renew the scientific basis for such Id immunization.

KW - High-dose therapy

KW - Idiotypic vaccination

KW - Multiple myeloma

UR - http://www.scopus.com/inward/record.url?scp=0031201101&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031201101&partnerID=8YFLogxK

M3 - Article

C2 - 9310193

AN - SCOPUS:0031201101

SN - 1083-8791

VL - 3

SP - 157

EP - 163

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

IS - 3

ER -

Rationale for adjuvant idiotypic vaccination after high-dose therapy for multiple myeloma

Abstract

Keywords

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this